Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genaissance Pharmaceuticals has entered into an agreement with Organon, a division of Akzo Nobel, to develop improved ways of testing responses to drugs in the treatment of psychiatric disorders.
Subscribe to our email newsletter
The companies will use Genaissance’s HAP Technology for pharmacogenetic research to discover genetic markers that show individual responses to drugs. They will then aim to create diagnostic tests that will guide therapy, based on the research.
Pharmacogenetic research is based on the fact that there are large “interindividual” differences in the response to drugs, be it therapeutic efficacy or unwanted side effects.
Under the terms of the agreement, Genaissance will receive license and research funding fees from Organon. In addition, Genaissance has certain rights for the development and commercialization of companion genetic tests. Organon and Genaissance are both eligible to receive royalties on revenues generated from diagnostic products resulting from the collaboration.
“We are pleased to be working with Organon as they integrate pharmacogenomics into their drug development pipeline,” said Kevin Rakin, president and CEO of Genaissance Pharmaceuticals. “We believe this agreement is an indication of the role and importance pharmacogenomics can play in improving the success rate of clinical trials and bringing innovative drugs to the market.”